Jinming Gao, PhD, UT Southwestern Medical Center, Dallas, TX, discusses the potential to exploit current nanoparticle encapsulation technology to deliver potent immune cytokines such as IL-15 and IL-12. Current research is evaluating this technology in non-human primates to assess the safety profile of the current formulation. A benefit of these nanoparticles is that they can be frozen and thawed with no aggregation. The next steps for research in this area include scaling up production size and evaluation for clinical use. This interview took place at the 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC 2022) in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
